Related Experiment Videos
[Clinical effects of K-18 (IgG-melphalan) in hypoplastic leukemia: a case report]
I Takahashi1, E Ohmoto, H Nakada
1Dept. of Medicine, Okayama University Medical School.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1988
Abstract:
Five cases of hypoplastic acute myelocytic leukemia were treated with an IgG-melphalan conjugate, K-18. Eight tablets of K-18, containing 30 mg per tablet, were given daily. One patient, a 68-year-old female, obtained complete remission with a duration of 1.5 + months. Among the four remaining patients without remission, one showed a decrease in leukemic cells in the peripheral blood. No side effects of K-18 were observed except in one patient, showing a slight increase in serum GOT and GPT levels. Further studies with a large group will be necessary to clarify the effect of this drug on hypoplastic leukemia.